NSCLC, especially lung adenocarcinoma, is characterized by a high frequency of driver mutations in oncogenes including EGFR, KRAS, STK11, MET, ALK, ERBB2/3, FGFR1/2/3, ROS, and RET [1]. This evidence concerns the gene MET and non-small cell lung carcinoma.